BIOMARX PHARMA

Company Snapshot

Founded: 2023
Entity Type: Private
Region: India
Headquarter: Uttar Pradesh, India
Key Geographics: India
Corporate Address: A-46, Ground Floor Sector 2 Near - Sector 15 Metro Station Noida, Uttar Pradesh 201301 India Tel. +91- 96957118075 www.biomarxpharma.com

Company Overview

BiomaRx, founded as a spinout from Harvard University, is developing liquid biopsy-based diagnostics for cancer applications, with an emphasis on pancreatic cancer.

The initial product, called Bio Pan-Cancer, is for use on patients who are in high-risk groups for pancreatic cancer, including those with inheritable pancreatic cancer or with pancreatitis or diabetes. The Bio Pan-Cancer test uses a panel of biomarkers including both proteins and RNA, and the technology format is still being worked out. The key aspect of the test is this panel of biomarkers, which was shown to be able to differentiate pancreatic cancer and healthy pancreas tissue, and able to be used to detect the presence of pancreatic cancer as early as Stage 2.

In February 2017 BiomaRx began a collaborative effort with SHG Sciences and Woodland Biosciences. SBH Sciences provided 10 biomarker platforms and laboratory facilities; Woodland Biosciences provided expertise for studying metabolic disease and oncology.

BIOMARX PHARMA In Reports

Global DNA Read, Write and Edit Market

The global market for DNA read, write and edit applications should grow from $17.0 billion in 2019 to $43.1 billion by 2024 with a compound annual growth rate of 20.5% during the period of 2019-2024.

Liquid Biopsy with Emphasis on Cancer: Global Markets to 2023

Get an overview of the global markets for liquid biopsy technologies, applications, industry subsegments along with analyses of global market trends with data from 2017, 2018 and projections of CAGRs through 2023 ...

Global DNA Sequencing: Research, Applied and Clinical Markets

The global DNA sequencing market was $10.7 billion in 2018 and is forecast to increase at a compound annual growth rate of 18.0% to reach $24.4 billion in 2023.

Company's Business Segments

  • Healthcare Solutions : The company develops, manufactures, and distributes advanced nutraceutical medicines that are formulated to support overall health and promote a balanced lifestyle.

Applications/End User Industries

  • Healthcare
  • Life Sciences
AI Sentiment